Unlike most private equity General Partners (GP), Amit Varma doesn’t mince words when he insists that private equity is a simple business. That may not explain how he exceeds his own estimates every time he sets out to raise a fund but it surely allows his growth equity fund, Quadria Capital, to punch above its weight.

When we first spoke in December, Varma, a trained medical doctor, was in Dubai closing a deal. He wouldn’t disclose much, except that it was in the postoperative rehab space. In 2020, Varma and his co-founder and managing partner Abrar Mir closed a US$600 million fund. Meant to raise only US$400 million, it will eventually end up investing US$800 million to US$1 billion. A second, smaller venture capital (VC)-like fund, Health Quad, will exceed its US$100 million target to close at US$150 million in April.

Varma headed up critical care at Fortis Healthcare—he continues to maintain his practising licence in India and the United States—when he returned to India in 1999. In crossing over to investment, he ran the Milestone-Religare investment franchise with Mir, earning their Southeast Asia credentials with a slew of deals. When the assets were amalgamated with the Fortis group, the duo had their “Hurrem” moment—to start a fund of their own.

In 2013, Quadria acquired acquired Livemint Quadria buys Milestone Religare Investment Advisors Read more the Milestone-Religare joint venture, raised money, and chose to headquarter itself in Singapore, “far ahead of the Mauritius post-boxes and all the attendant issues”. Capital would eventually get regulated so why kick the can down the regulatory road?

Today, as a double niche fund—focussed only on healthcare in South and Southeast Asia—Quadria is making ambitious bets in the region. In four years, Varma believes, Asia’s healthcare market will grow more than that of the US and Europe combined. He spends six months travelling through the ASEAN ASEAN ASEAN The Association of Southeast Asian Nations is an intergovernmental organisation comprising 10 SEA nations and six months in India where 30% of the Quadria fund is deployed. He also runs a tight ship, with just 15 people in Singapore and 10 in India.

Varma’s bullishness comes from his math that the addressable market is in Asia; the US market is only nice to have. He details them out in this interview, a calculus of investing with deductions in sets of two, three or four arguments.

The Interview:

The Ken: Let’s start with your career. You practised critical care for nearly 20 years, both in India and the US, and then became an investor. Why do you believe doctors should understand profit and loss?

When I studied medicine, it was considered an honourable profession.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Read this story. Subscribe Now

This story is available across both editions. Subscribe to the one that’s most relevant for you. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.